Bristol-Myers Squibb Co. (BMY) News
Filter BMY News Items
BMY News Results
|Loading, please wait...|
BMY News Highlights
- BMY's 30 day story count now stands at 35.
- Over the past 27 days, the trend for BMY's stories per day has been choppy and unclear. It has oscillated between 1 and 22.
- The most mentioned tickers in articles about BMY are DRUG, AMP and BEAT.
Latest BMY News From Around the Web
Below are the latest news stories about BRISTOL MYERS SQUIBB CO that investors may wish to consider to help them evaluate BMY as an investment opportunity.
Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with one culprit being the loss of exclusivity for one of its blockbuster drugs, Revlimid. The blood cancer therapy reported sales of $2.4 billion, down 28% year over year.
Bristol-Myers Squibb ( NYSE:BMY ) Full Year 2022 Results Key Financial Results Revenue: US$46.2b (flat on FY 2021). Net...
NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Companies in The news Are: META, BMY, PH, CAH.
Bristol-Myers Squibb Company (BMY)
Q4 2022 Earnings Conference Call
February 2, 2023 9:00 AM ET
Timothy Power - VP & Head, IR
Giovanni Caforio - Chairman & CEO
David Elkins - EVP & CFO
Christopher Boerner - EVP & Chief Commercialization Officer
Samit Hirawat - EVP & Chief Medical Officer, Global Drug Development
Conference Call Participants
Geoffrey Meacham - Bank of America
Chris Shibutani - Goldman Sachs
Christopher Schott - JPMorgan
Seamus Fernandez - Guggenheim Securities
Stephen Scala - Cowen and Company
Timothy Anderson - Wolfe Research
Evan Seigerman - BMO Capital Markets
Terence Flynn - Morgan Sta...
The Big Pharma axe: Merck cuts chikungunya vax, Bristol Myers drops CytomX-partnered programs, and more
As fourth quarter earnings come in, Big Pharmas are disclosing changes to their pipelines during their investor calls, and sometimes more quietly in presentation appendices. Merck dropped its chikungunya vaccine candidate, which completed a Phase II study. Merck acquired the vaccine through its purchase of Themis Bioscience in 2020. In
Bristol Myers Squibb Co on Thursday reported quarterly earnings that beat analysts'' estimates due to a smaller-than-expected drop in sales of cancer drug Revlimid, which is facing competition from cheaper generic rivals.
If you''re a long-term BMY bull, here''s what the charts suggest….BMY
Revlimid Generic Competition Hurts Bristol Myers'' Q4 Earnings, Issues Annual Outlook Within Expected Range
Bristol Myers Squibb & Co (NYSE: BMY ) said that its Q4 sales of $11.41 billion fell 5% Y/Y as generic competition impacted sales of its blockbuster cancer drug Revlimid in the U.S. and foreign exchange impacts, partially offset by in-line products (primarily Opdivo) and new product portfolio (primarily Opdualag and Abecma). Analysts estimated Q4 sales of $11.20 billion. Sales of Revlimid fell 32% to … Full story available on Benzinga.com
Pharmaceutical majors Merck & Co (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY), and Eli Lilly & Co (NYSE:LLY) have reported fourth-quarter numbers at…